• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

DDI Webinar - Introduction to Post-Marketing Drug Safety Surveillance - February 26, 2013

 

The Food and Drug Administration, Center for Drug Evaluation and Research (CDER), is delighted to inform you of a unique opportunity for healthcare professionals, pharmacy students, nurse practitioner students and medical students in the United States to learn more about the FDA and drug regulation. CDER's Division of Drug Information (DDI) is offering a series of educational webinars, developed by FDA pharmacists and targeted to the needs of all healthcare professionals and students.
 
These focused webinars support FDA's mission of promoting and protecting public health, through interaction and education to strengthen relationships with future clinicians, researchers, nurses, and pharmacists. Fostering this connection will provide a better understanding of FDA's role in public health as a regulatory agency.
 

On February 26, 2013, CDER's Office of Communication, Division of Drug Information (DDI) hosted a webinar titled: "Introduction to Post-Marketing Drug Safety Surveillance," the featured speaker, LT Andrew J. Fine, Pharm.D., BCPS, gave an overview of pharmacovigilance: the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other drug-related problems.

Adobe, the Adobe logo, Acrobat and Acrobat Connect are either registered trademarks or trademarks of Adobe Systems Incorporated in the United States and/or other countries.